Search

Resume Objectif Evaluer l’influence de l’epanchement articulaire sur la reponse clinique a une injection unique d’Hylane GF-20 chez des patients souffrant de coxarthrose. Methode Patients souffrant de coxarthrose inclus prospectivement pour traitement intra-articulaire par Hylane GF-20. La severite de la coxarthrose a ete appreciee par le stade radiographique de Kellgren et Lawrence. La presence d’un epanchement a ete objectivee par echographie (epanchement articulaire : Ep+ ; absence d’epanchement : Ep−). Les parametres suivants ont ete evalues a l’inclusion, un (m1), trois (m3) et six mois (m6) apres l’injection : EVA douleur, indice algofonctionnel de Lequesne (IAFL) et score de WOMAC. La proportion de patients repondeurs selon les criteres OARSI ou ayant atteint les valeurs du patient acceptable symptom state (PASS) a ete analysee dans la population totale et selon la presence ou non d’un epanchement echographique initial. Resultats Sur les 55 patients inclus, 24 (44 %) presentaient un epanchement articulaire. Dans ce groupe, l’IAFL etait plus eleve a l’inclusion que dans le groupe sans epanchement (11,9 ± 3,6 versus 8,4 ± 4,5) ( p = 0,003). Dans la population totale, la proportion de repondeurs (criteres OARSI) etait a m1, m3 et m6 respectivement de 31,8, 39,4 et 14,8 %. De meme, la proportion de patients atteignant les valeurs du PASS douleur et fonction etait respectivement a m1, 52,4 et 50 %, a m3, 67,7 et 54,5 %, et a m6, 60 et 50 %. La presence d’un epanchement n’a pas modifie la reponse au traitement. Conclusion La presence d’un epanchement articulaire est associee a un retentissement algofonctionnel initial plus severe mais n’influence pas la reponse a l’Hylane GF-20 dans la coxarthrose.

Objective To evaluate the influence of a joint effusion on the clinical response to a single injection of Hylan GF-20 for hip osteoarthritis. Method We prospectively included patients scheduled for intraarticular Hylan GF-20 injection to treat hip osteoarthritis. Disease severity was assessed based on the Kellgren-Lawrence radiological grade. Ultrasonography was performed to look for a joint effusion. The pain score on a visual analog scale, Lequesne algofunctional index, and WOMAC scores were recorded at baseline and 1, 3, and 6 months postinjection. The proportions of patients who met OARSI response criteria and who achieved Patient Acceptable Symptom State (PASS) thresholds were determined in the overall population and in the groups with and without a joint effusion at baseline. Results Of 55 included patients, 24 (44%) had an effusion at baseline. The baseline Lequesne index was significantly higher in the group with an effusion (11.9 ± 3.6 versus 8.4 ± 4.5) ( p = 0.003). The proportions of OARSI responders in the overall population were 31.8%, 39.4%, and 14.8% after 1, 3, and 6 months, respectively. The proportions of patients who achieved the PASS for pain and function were 52.4% and 50.0% after 1 month, 67.7% and 54.5% after 3 months, and 60.0% and 50.0% after 6 months, respectively. Presence of an effusion at baseline had no effect on any of the clinical response parameters. Conclusion Presence of a joint effusion is associated with worse pain and functional impairment at baseline but has no influence on the clinical response to Hylan GF-20 in patients with hip osteoarthritis.